Full Text
CG-DL-E-27082026-275841
EXTRAORDINARY
PART II—Section 3—Sub-section (ii)
6634 GI/2026
(1)
MINISTRY OF CHEMICALS AND FERTILIZERS
(Department of Pharmaceuticals)
(NATIONAL PHARMACEUTICAL PRICING AUTHORITY)
ORDER
New Delhi, the 27th August, 2026
S.O. 4780(E).— In implementation of directions of review order issued by the Department of Pharmaceuticals
(DoP) under para 31 of Drugs (Prices Control) Order, 2013 vide order specified in column (7) of the table below and in
exercise of the powers conferred by paragraphs 5,11 and 15 of the Drugs (Prices Control) Order, 2013, read with
S.O. 1394(E) dated the 30th May, 2013 and S.O. 5249(E) dated 11th November, 2022 issued by the Government of
India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the
Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. No. and date specified in the
Column (7) of the table, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes,
the price as specified in column (5) of the table herein below as the retail price, exclusive of Goods and Services Tax,
if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the
strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns
(3), (4) and (8) thereof;
TABLE
| S. No. | Name of the Formulation | Dosage form & Strength | Unit | Retail Price (Rs.) | DoP Review no. & Date | Existing SO number & date | Manufacturer & Marketing Company respectively |
|---|---|---|---|---|---|---|---|
| (1) | (2) | (3) | (4) | (5) | (6) | (7) | (8) |
| 1. | Paracetamol, Phenylephrine HCl, Chlorpheniramine Maleate, Ammonium Chloride, Sodium Citrate & Menthol suspension | Each 5ml (teaspoonful) contains: Paracetamol IP 250 mg Phenylephrine Hydrochloride IP 5 mg Chlorpheniramine Maleate IP 2 mg Ammonium Chloride IP 120 mg Sodium Citrate IP 60 mg Menthol IP 1 mg | 1 ml | 0.70 | 31015/06/2025- Pricing (E-36772) dated 21.05.2026 | 3563(E) dated 01.08.2025 (at Sl. No. 36) | M/s Windlas Biotech Limited / M/s Biological E. Limited |
Note:
(a)
The manufacturer as specified in column (8), of the above mentioned formulations i.e. “new drug” under
paragraph 2(1)(u) of the DPCO, 2013 may revise the retail price as specified in column (5) of the table
hereinabove.
(b)
The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the
Government on the retail price mentioned in column (5) of the above said table.
(c)
The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in
accordance with the retail price specified in column (5) of the above table as per provisions contained in paragraph
11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per
paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d)
As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list,
if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a
manner so as to be easily accessible to any person wishing to consult the same.
(e)
The above mentioned retail prices are applicable only to the manufacturer / marketer as mentioned above for
generic / any brand of the same composition / strength of the subject formulations, subject to fulfilment of all the
applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing
license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable,
by the concerned manufacturers/marketing companies.
(f)
In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification
and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit
the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the
Essential Commodities Act, 1955.
(g)
Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with
the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column
(3) & (8) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that
Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (8) thereof, if
any, issued prior to this notification, stand(s) superseded.
[PN/282/150/2026/F/F. No. 8(150)/2026/D.P./NPPA-Div.-II]
BHIVA RAM YADAV, Assistant Director
and Published by the Controller of Publications, Delhi-110054.
RAVINDER KUMAR
KUMAR
Date: 2026.08.27 21:21:59 +05'30'
Login to read full text